0001209191-23-028521.txt : 20230510
0001209191-23-028521.hdr.sgml : 20230510
20230510172801
ACCESSION NUMBER: 0001209191-23-028521
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230508
FILED AS OF DATE: 20230510
DATE AS OF CHANGE: 20230510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Anish Bhatnagar
CENTRAL INDEX KEY: 0001614821
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36593
FILM NUMBER: 23907857
BUSINESS ADDRESS:
STREET 1: 3 TWIN DOLPHIN DRIVE
STREET 2: SUITE 160
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-213-8444
MAIL ADDRESS:
STREET 1: 3 TWIN DOLPHIN DRIVE
STREET 2: SUITE 160
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC
CENTRAL INDEX KEY: 0001484565
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 770523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 203 REDWOOD SHORES PARKWAY
STREET 2: SUITE 500
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-213-8444
MAIL ADDRESS:
STREET 1: 203 REDWOOD SHORES PARKWAY
STREET 2: SUITE 500
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: Capnia, Inc.
DATE OF NAME CHANGE: 20100219
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-08
0
0001484565
SOLENO THERAPEUTICS INC
SLNO
0001614821
Anish Bhatnagar
203 REDWOOD SHORES PKWY, STE 500
REDWOOD CITY
CA
94065
1
1
0
0
Chief Executive Officer
0
Warrants (right to buy)
1.75
2023-05-08
4
A
0
2143
0.4425
A
2023-05-08
Common Stock
2143
2143
D
Warrants (right to buy)
2.50
2023-05-08
4
A
0
3500
0.4425
A
2023-05-08
Common Stock
3500
3500
D
The Warrants were acquired pursuant to a Securities Purchase Agreement, dated December 16, 2022, between the Issuer and certain entities and members of the Issuer's management team. The acquisition was approved by the Issuer's Board of Directors and constitutes an exempt acquisition under Rule 16b-3(d)(1) of the Securities Exchange Act of 1934, as amended.
The Warrants will expire upon the earlier of (i) 30 days following announcement of positive top-line data from the randomized withdrawal period of Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS), or (ii) November 8, 2026.
The Warrants will expire upon the earlier of (i) 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS or (ii) November 8, 2026.
/s/ Anish Bhatnagar
2023-05-10